Journal Basic Info
- Impact Factor: 1.809**
- H-Index: 6
- ISSN: 2474-1655
- DOI: 10.25107/2474-1655
Major Scope
- Sports Medicine
- Family Medicine and Public Health
- Cardiovascular Medicine
- Pneumonia
- Infectious Disease
- Epidemiology
- Orthopedics & Rheumatology
- Medical Radiography
Abstract
Citation: Ann Clin Case Rep. 2023;8(1):2522.DOI: 10.25107/2474-1655.2522
Guillain-Barré Syndrome Related to Pembrolizumab in Metastatic Triple Negative Breast Cancer
Wu D, Liu Y, Zhao J* and Zheng L*
Department of Neurology, Minhang Hospital, Fudan University, China
PDF Full Text Case Report | Open Access
Abstract:
Immune Checkpoint Inhibitors (ICIs) are increasingly application in the treatment of advanced cancers these years, exhibiting the potential to be the primary method in oncotherapy. However, with the applying of ICIs, the immune-related Adverse Events (irAEs) were also reported gradually. Here, we reported a 51-year-old female with metastatic Triple Negative Breast Cancer (TNBC) developing into Guillain-Barré Syndrome (GBS) after receiving four months of anti-Programmed cell Death protein 1 (PD-1) antibodies treatment with pembrolizumab and we discussed the diagnose and treatment of GBS related to irAEs.
Keywords:
ICI; TNBC; GBS; PD-1
Cite the Article:
Wu D, Liu Y, Zhao J, Zheng L. Guillain-Barré Syndrome Related to Pembrolizumab in Metastatic Triple Negative Breast Cancer. Ann Clin Case Rep. 2023; 8: 2522..
Search Our Journal
Journal Indexed In
